Table 3:

Response to fulvestrant, palbociclib and erdafitinib combination according to FGFR1-4 amplification status

	All patients	FGFR1-4 amp	FGFR1-4 non-amp
Total number of cases	35	29	6
Evaluable for efficacy	31	27	4
Best Overall Response
CR	0	0	0
PR	3 (10%)	2 (8%)	1 (25%)
SD	17 (55%)	16 (59%)	1 (25%)
PD	11 (35%)	9 (33%)	2 (50%)
Non evaluable	4	2	2
Clinical Benefit Rate at 6 months	23%	22%	25%
Duration of overall response range	18-112 w	18-39 w	122 w
Median progression free survival (range)	12 w (5-144w)	12 w (6-55w)	13 w (5-144w)